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Betahistine are routine drug in neurological practice, which is used to correct vertigo. The clinical efficacy of this drug can 
be caused not only by neuro-, but also by endotheliotropic action. In this review, the main information on the potential 
mechanisms for the implementation of vasoprotection, including metabolic, NO-ergic, anti-inflammatory and other 
components of the action are discussed. Betahistine as histamine receptors type 3 antagonist and histamine receptors type 1 
and 2 agonist has a positive effect on cerebral and systemic hemodynamics, and due to anorexigenic action and the ability 
to stimulate lipolysis can ameliorate dyslipidemia as well as suppress the synthesis of pro-inflammatory cytokines and 
increase the expression of endothelial NO synthase. 
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Introduction 
Neurological disorders such as vertigo, attention 
deficit, cognitive decline, and fatigue are among the 
most common symptoms in women of menopausal 
age. The etiology of this kind of symptoms is 
different, but the most obvious cause is dyscirculatory 
cerebral blood flow disorders, associated, among 
other, with endocrinological alterations and 
endothelial dysfunction typical of this age [1]. 
The close coherence of endothelial function (ED) 
with cerebral hemodynamic abnormalities allows us 
to consider the endothelium as an important target of 
therapeutic effects. Widely known that the endothelial 
monolayer is the largest endocrine organ and its 
functional activity is associated with the regulation of 
hemodynamics, coagulation, local inflammation, 
angiogenesis and many other processes. Endothelial 
dysfunction leads to hypertension, impaired normal 
tissue perfusion, the appearance of a tendency to 
thrombosis and pathological changes in the vascular 
network anatomy. Changes in the spectrum of 
molecules secreted and expressed by the endothelium 
and a violation of its barrier function ultimately lead 
to infiltration of the vascular wall with atheromatous 
masses and the formation of atherosclerotic plaques 
[2]. 
With the aim to improve the effectiveness of 
underlying disease treating and reduce the risk of 
developing life-threatening vascular complications, 
pharmacological correction of neurological symptoms 
associated with impaired brain blood supply should be 
carried out using drugs that have not only neuro-, but 
also endothelium-protective activity. Since betahistine 
is one of the most commonly prescribed drugs in 
neurological practice (Fig. 1), it seems appropriate to 
evaluate its pharmacodynamics from the point of view 
of the effect on endothelium function. 
 
Figure -1: The structure of drugs for the vertigo 
treatment [3] 
Betahistine, Histamine and Endothelium 
At the beginning of the 20th century, the future 
Nobel laureate from London, Henry Dale (Henry 
Dale) worked on the detection of compounds 
responsible for improving uterine tone when using an 
extract of ergot [5]. In 1910, the search led to the 
discover of histamine, and the description of its 
phenotypic effects, such as vasodilation, increased 
tone of the smooth muscles of the internal organs, as 
well as a positive chrono-and inotropic effect [6]. 
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After another 10 years, Popelsky in experiments on 
dogs discovered the ability of histamine to increase 
the secretion of hydrochloric acid in the stomach [7]. 
Finally, in 1937, William Feldberg and staff provided 
compelling evidence that histamine is a mediator of 
experimental anaphylaxis [8, 9]. Studies of the second 
half of the 20th century were marked by the 
identification of histamine molecular targets — 
histamine receptors (HR) of types 1, 2, 3, cloning of 
their genes, and the synthesis and study of a wide 
range of compounds having chemical affinity for 
them, mainly antagonists [10]. Then, already in the 
21st century, using the bioinformatics screening, 
histamine receptor of type 4 was discovered, whose 
functions are mainly limited to immune regulation 
[10-12]. H3R are predominantly expressed in the 
brain, where they provide modulation processes for 
synaptic transmission. They are characterized by high 
spontaneous activity and the ability to inhibit the 
neuronal liberation of histamine. The therapeutic 
potential of this type of blockade, receptors, includes 
the treatment of vertigo, narcolepsy, attention deficit, 
Alzheimer's disease, allergic rhinitis, and some other 
pathologies [13]. 
Betahistine was registered in 1970 as a drug for the 
treatment of Meniere's disease. He is a selective H3 
antagonist and an H1 and H2 receptor agonist. While 
the blockade of H3R causes mainly vestibulotropic 
effects, effects on H1R and H2R can cause 
endothelioprotective action. 
Hemodynamic Effects of Betahistine 
Violation of the endothelium vasoregulatory 
function leads to the appearance of permanent 
vasoconstriction. At the same time, hypertension is a 
factor contributing to damage to the endothelial 
monolayer. As a result, a kind of vicious circle is 
created, the gap of which is one of the important tasks 
of pharmacotherapy. 
Histamine receptors are widely expressed in the 
endothelium, responding mainly to controlling 
vascular tone and permeability. The H1 and H2 
receptors are involved in endothelium-dependent 
vasodilation, which is prevented by prior 
administration of the blocker of the endothelial NO 
synthase L-NAME [14].  
A particularly important role is played by 
histamine receptors in the regulation of cerebral blood 
flow, where their activation may be accompanied by 
both contraction and relaxation of blood vessels. At 
the same time, vasodilation is a more stereotypical 
response and is also mediated by endothelium [15]. 
Following the histamine infusion, a two-phase drop in 
blood pressure occurs, which is implemented initially 
through the H1 and then through the H2 receptors. 
The hemodynamic effect of the H1R and H2R 
agonists with respect to the small steep circulation has 
the opposite direction and is expressed in an increase 
in pulmonary pressure [16]. 
Betahistine and Inflammation 
Acute or permanent inflammation, leading to 
cytokinemia and reactive oxygen species increased 
production is one of the factors contributing to the 
development and progression of ED [17]. The ability 
of drugs to reduce the excess activity of the adaptive 
and innate parts of the immune system can be 
considered as part of the endothelioprotective action. 
Although the histaminergic system is classically 
associated with a proinflammatory focus, 
experimental studies in animal models have shown 
that phlogogenic potential mainly has H1R, while the 
action of other subtypes of histamine receptors is not 
so clear. Thus, the inflammatory infiltration of the 
brain by neutrophils after the simulation of focal 
ischemia is reduced almost 2 times against the 
background of the introduction of L-histidine [18]. 
This effect is due to the ability of histamine to reduce 
the production of IL-12 through H2R and is prevented 
by the introduction of ranitidine [19, 20]. Histamine, 
as a classic edemogenic agent, after intra-arterial 
injection into the carotid artery increases 
transcapillary penetration of albumin into brain tissue 
(again through H2R) [21, 22]. However, against the 
background of the already existing edema, activation 
of the histaminergic system leads to a decrease in the 
content of transudate in the affected areas [23]. This 
phenomenon may be due to both a decrease in 
capillary permeability and the ability of histamine to 
reduce neuronal excitotoxicity [24]. 
In vitro treated by with a histamine solution (from 
10–5 to 10–7 M) macrophages showed a decrease in 
chemotaxis, production of superoxide anions, and 
macrophage phagocytic activity. In addition, 
histamine and the H2R agonist dimaprit inhibited 
TNF-α and IL-12 production induced by 
lipopolysaccharide, as well as the expression of the 
ICAM-1 molecule on monocytes (Fig. 3) [25, 26]. 
In animal models of local inflammation, 
betahistine reduces the severity of arthritis and levels 
of pro-inflammatory cytokines, including TNF-α, IL-
6, IL-23, and IL-17 in mouse paw tissues. Lymph 
node cells in mice treated with betahistine are 
characterized by a decrease in proliferation, as well as 
a lower Th17 content [27]. 
Metabolic Effects of Betahistine 
The endothelium is one of the most vulnerable 
organs experiencing the damaging effects of 
dysmetabolic disorders. Improving the metabolic 
profile is considered as one of the promising strategies 
for the correction of endothelial dysfunction [28-31]. 
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In this regard, the fact that betahistine has 
anorexigenic properties and the ability to stimulate 
lipolysis is especially intriguing. 
Numerous experiments have shown that the brain 
histaminergic system plays a role in the pathogenesis 
of obesity. Intracerebral administration of histamine, 
systemic use of its precursor L-histidine and H3-R 
blockade reduce food intake, body weight and 
improve the rodent lipid profile [32-35]. In contrast, 
administration of the alpha-fluoromethylhistidine, 
histidine-decarboxylase inhibitor and intraventricular 
injection of H1-R antagonists increase food intake in 
rodents [36]. Similarly, transgenic mice with reduced 
H1-R and histidine carboxylase expression develop 
hyperphagia, obesity, and diabetes [37–40]. These 
data are confirmed in clinical studies. So, one of the 
side effects of the drug for the treatment of 
schizophrenia olanzapine is obesity [41]. This effect is 
presumably associated with the presence of 
histaminergic action in it and is leveled with 
simultaneous use with betahistine [42-45]. 
The positive metabolic effects of H1R agonists are 
also due to the peripheral component of the action. 
Thus, the use of betahistine enhances the expression 
of enzymes involved in lipolysis and inhibition of 
lipogenesis in the liver by activating the receptor 
activated by peroxisome proliferator (PPAR-α) (Fig. 
3) [46].  
PPAR-α is known to be the target of antidiabetic 
drugs of the thiazolidinediones group and associated 
with an increase in glucose utilization, normalization 
of energy metabolism and contributes to an increase 
in eNOS activity in endothelial cells [47, 48]. 
Conclusion and Perspectives 
Thus, betahistine has a large range of potential 
ways to achieve endothelioprotective action, which 
include an improvement in the metabolic profile, a 
positive effect on hemodynamics, a decrease in pro-
inflammatory activation and NO-ergic activity. 
Accumulated clinical experience indicates that 
betahistine has a positive effect on cerebral blood 
flow, but its effect on peripheral hemodynamics and 
atherothrombogenesis processes may be a subject of 
further study.  
Search and study of drugs that improve endothelial 
function is an important task of modern pharmacology 
[49-57]. Special attention should be paid to remedies 
that, along with the treatment of the underlying 
disease, reduce the risk of other pathologies and 
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